Evidence map›Paper›PMID 33204397›Full record

ArticleOxidative medicine and cellular longevity2020

Selective Targeting of Cancerous Mitochondria and Suppression of Tumor Growth Using Redox-Active Treatment Adjuvant.

Rumiana Bakalova, Severina Semkova, Donika Ivanova, Zhivko Zhelev, Thomas Miller, Tsuguhide Takeshima, Sayaka Shibata, Dessislava Lazarova, Ichio Aoki, Tatsuya Higashi

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oxidative medicine and cellular longevity, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 31 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Anticancer Activity of Aqueous Extracts fromMolecules (Basel, Switzerland) · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Rumiana BakalovaQuantum-State Controlled MRI Group, Institute for Quantum Life Science, National Institutes for Quantum and Radiological Science and Technology (QST), 4-9-1 Anagawa, Chiba 263-8555, Japan.ORCID https://orcid.org/0000-0002-5309-3250
Severina SemkovaQuantum-State Controlled MRI Group, Institute for Quantum Life Science, National Institutes for Quantum and Radiological Science and Technology (QST), 4-9-1 Anagawa, Chiba 263-8555, Japan.
Donika IvanovaFaculty of Veterinary Medicine, Trakia University, 11 Armejska Str., Stara Zagora 6000, Bulgaria.
Zhivko ZhelevInstitute of Biophysics and Biomedical Engineering, Bulgarian Academy of Sciences, 21 Acad. G. Bonchev Str., Sofia 1113, Bulgaria.
Thomas MillerIC-MedTech Co., San Diego, CA, USA.
Tsuguhide TakeshimaRadiation and Cancer Biology Group, Department of Charged Particle Therapy Research, National Institute of Radiological Sciences (NIRS), QST, 4-9-1 Anagawa, Chiba 263-8555, Japan.
Sayaka ShibataQuantum-State Controlled MRI Group, Institute for Quantum Life Science, National Institutes for Quantum and Radiological Science and Technology (QST), 4-9-1 Anagawa, Chiba 263-8555, Japan.
Dessislava LazarovaMedical Faculty, Sofia University, 1 Koziak Str., Sofia 1407, Bulgaria.
Ichio AokiQuantum-State Controlled MRI Group, Institute for Quantum Life Science, National Institutes for Quantum and Radiological Science and Technology (QST), 4-9-1 Anagawa, Chiba 263-8555, Japan.
Tatsuya HigashiFunctional and Molecular Imaging Team, Department of Molecular Imaging and Theranostics, National Institute of Radiological Sciences (NIRS), QST, 4-9-1 Anagawa, Chiba 263-8555, Japan.ORCID https://orcid.org/0000-0002-8338-4737
Medical University of Sofia · BGNational Institutes for Quantum Science and Technology · JPTrakia University · BGBulgarian Academy of Sciences · BG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Redox-active substances and their combinations, such as of quinone/ascorbate and in particular menadione/ascorbate (M/A; also named Apatone®), attract attention with their unusual ability to kill cancer cells without affecting the viability of normal cells as well as with the synergistic anticancer effect of both molecules. So far, the primary mechanism of M/A-mediated anticancer effects has not been linked to the mitochondria. The aim of our study was to clarify whether this "combination drug" affects mitochondrial functionality specifically in cancer cells. Studies were conducted on cancer cells (Jurkat, Colon26, and MCF7) and normal cells (normal lymphocytes, FHC, and MCF10A), treated with different concentrations of menadione, ascorbate, and/or their combination (2/200, 3/300, 5/500, 10/1000, and 20/2000

Indexed as

AnimalsAntineoplastic Combined Chemotherapy ProtocolsApoptosisAscorbic AcidCell ProliferationChemotherapy, AdjuvantFemaleHumansJurkat CellsMCF-7 CellsMelanoma, ExperimentalMembrane Potential, MitochondrialMiceMice, Inbred C57BLMitochondriaNeoplasmsAscorbic AcidReactive Oxygen SpeciesVitamin K 3Vitamins

Identifiers

PMID33204397
PMCPMC7652615
OpenAlexW3095308022

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.